Primary Cutaneous Plasmacytoma Treated with Palliative Radiotherapy: A Case Report and Literature Review
Main Article Content
Keywords
plasmacytoma, plasma cell neoplasm, skin neoplasm
Abstract
Introduction: Primary cutaneous plasmacytomas (PCP) are very rare plasma cell neoplasms present in the skin or subcutaneous tissue without underlying multiple myeloma (MM).
Case Report: A 78-year-old man was referred to dermatology by wound care for a three-year history of non-healing, enlarging, bleeding lesions on the right lower extremity. Examination revealed multiple firm, tender, slightly mobile erythematous to violaceous nodules ranging from 1 to 5 cm in size, some with erosion and heme crusting. Histopathologic analysis of skin biopsies showed an expansile nodular plasmacytic infiltrate in the dermis. A diagnosis of PCP was made based on clinical and histopathological features. Our patient underwent palliative radiation and responded to the therapy with decrease in size of all lesions
Conclusion: We present a case of PCP presenting as multiple erythematous nodules as opposed to a solitary neoplasm, which likely represents a spectrum of variation of one tumor. To diagnose PCP, patients should not meet criteria for MM. All patients with new solitary plasmacytoma should be evaluated with skeletal survey or computed tomography, MRI, and PET/CT to rule out additional lesions. PCPs are usually indolent but 10% to 30% progress to MM within 10 years. Radiation therapy is considered the standard treatment, and additional clinical trials are underway to test the role of adjuvant chemotherapies.
References
2. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. doi:10.1016/S1470-2045(14)70442-5
3. Primary cutaneous plasmacytoma: report of a case with review of the literature - PubMed. Accessed April 17, 2021. https://pubmed.ncbi.nlm.nih.gov/11044834/
4. Walby ML, Ahluwalia J, Mehregan DR. Primary cutaneous plasmacytoma in an HIV-positive patient. Int J Dermatol. 2016;55(4):464-467. doi:10.1111/j.1365-4632.2012.05764.x
5. Rongioletti F, Patterson JW, Rebora A. The histological and pathogenetic spectrum of cutaneous disease in monoclonal gammopathies. J Cutan Pathol. 2008;35(8):705-721. doi:10.1111/j.1600-0560.2007.00884.x
6. Caers J, Paiva B, Zamagni E, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11(1):10. doi:10.1186/s13045-017-0549-1
7. Tsang RW, Campbell BA, Goda JS, et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;101(4):794-808. doi:10.1016/j.ijrobp.2018.05.009
8. Tsang DS, Le LW, Kukreti V, Sun A. Treatment and outcomes for primary cutaneous extramedullary plasmacytoma: A case series. Curr Oncol. 2016;23(6):e630-e646. doi:10.3747/co.23.3288
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.